Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.
Robert J. Kreitman(National Cancer Institute), Ira Pastan(National Institutes of Health), Liqiang Xi(Center for Cancer Research), Katherine R. Calvo(National Institutes of Health Clinical Center), Lacey James-Echenique(MRC Laboratory of Molecular Biology), Julie Feurtado(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Evgeny Arons(National Institutes of Health), Alina Dulau(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Irina Marić(Center for Cancer Research), Mark Raffeld(National Cancer Institute)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome
|Blood|2011|638
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519